The Beneficial Effect of Renin-Angiotensin-Aldosterone System Blockade in Treatment of Hypertension, Resistant to Conventional Antihypertensives, in Patients on Maintenance Hemodialysis
Background: Hypertension (HTN) is present in up to 90% of end stage kidney disease (ESRD) patients irrespective of the etiology of their kidney disease. Moreover, it is an important modifiable risk factor for progression to ESRD and its overall cardiovascular morbidity and mortality. Objective: to evaluate, prospectively, the role of Renin-Angiotensin-Aldosterone System blockade (RAAS) in HTN, resistant to 3 conventional antihypertensives, in patients on maintenance hemodialysis (MHD). Patients and methods: A total of 52 such patients were treated with Ramipril and 5 with Losartan after intolerable cough/shortness of breath following Ramipril-use. None of the patients had fluid depletion, renal artery stenosis and primary endocrinopathy. The study group was compared to a matched control group of MHD patients with normal blood pressure following 3 drugs-combination therapies. Results: All patients, with resistant HTN, had significant activation of RAAS system prior to treatment compared to inactive one in the control group. In those with resistant HTN, control of HTN, was established within 2 weeks of therapy and was associated with suppression of the RAAS. Such therapy was associated with minor side effects. Conclusion: Our study has shown that RAAS blockade is safe and effective in controlling such resistant HTN in MHD patients.
References
[1]
Agarwal, R., Nissenson, A., Battle, D., Coyne, D., Trout, J. and Warnock, D. (2003) Prevalence, Treatment, and Control of Hypertension in Chronic Hemodialysis Patients in the United States. American Journal of Medicine, 115, 291-297. https://doi.org/10.1016/S0002-9343(03)00366-8
[2]
Foley, R., Parfrey, P., Darnett, J., Kent, G., Murray, D. and Barre, P. (1996) Impact of Hypertension on Cardiomyopathy, Morbidity, and Mortality in End-Stage Renal Disease. Kidney International, 49, 1379-1385. https://doi.org/10.1038/ki.1996.194
[3]
Martinez-Maldonado, M. (1998) Hypertension in End-Stage Renal Disease. Kidney International, 54, S67-S72. https://doi.org/10.1046/j.1523-1755.1998.06816.x
[4]
United States Renal Data System USRDS (2010) Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, Bethesda, MD.
[5]
Levin, N.W., Kotanko, P., Eckardt, K.U., Kasiske, B.L., Chazot, C., Cheung, A.K., et al. (2010) Blood Pressure in Chronic Kidney Disease Stage 5D—Report from a Kidney Disease: Improving Global Outcomes Controversies Conference. Kidney International, 77, 273-284. https://doi.org/10.1038/ki.2009.469
[6]
James, P., Oparil, S., Carter, B., Cushman, W., Dennison-Himmelfarb, C., Handler, J., et al. (2014) Evidence-Based Guidelines for the Management of High Blood Pressure in Adults; Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). Journal of American Medical Association, 311, 507-520. https://doi.org/10.1001/jama.2013.284427
[7]
Yiannakopoulou, E.Ch., Papadopulos, J.S., Cokkinos, D.V. and Mountlkalakis, T.D. (2005) Adherence to Antihypertensive Treatment: A Critical Factor for Blood Pressure Control. European Journal of Cardiovascular Prevention and Rehabilitation, 12, 243-249. https://doi.org/10.1097/01.hjr.0000160601.41762.44
[8]
McCausland, F.R., Waikar, S.S. and Brunelli, S.M. (2012) Increased Dietary Sodium Is Independently Associated with Greater Mortality among Prevalent Hemodialysis Patients. Kidney International, 82, 204-211. https://doi.org/10.1038/ki.2012.42
[9]
Rimoldi, S., Scherrer, U. and Messerli, F. (2014) Secondary Arterial Hypertension: When, Who, and How to Screen? European Heart Journal, 35, 1245-1254. https://doi.org/10.1093/eurheartj/eht534
[10]
Medina, A., Bell, P.R.F., Briggs, J.D., Brown, J.J., Fine, A., et al. (1972) Changes of Blood Pressure, Renin, and Angiotensin after Bilateral Nephrectomy in Patients with Chronic Renal Failure. The British Medical Journal, 4, 694-696. https://doi.org/10.1136/bmj.4.5842.694
[11]
Elhage, O., Sahai, A., Challacombe, B., Murphy, D., Scoble, J. and Dasgupta, P. (2011) Role of Laparoscopic Nephrectomy for Refractory Hypertension in Poorly Functioning Kidneys. Annals of Royal College of Surgeons of England, 93, 25-26. https://doi.org/10.1308/003588410X12771863936800
[12]
Agarwal, R., Lewis, R., Davis, J.L. and Becker, B. (2001) Lisinopril Therapy for Hemodialysis Hypertension: Hemodynamic and Endocrine Responses. American Journal of Kidney Diseases, 38, 1245-1250. https://doi.org/10.1053/ajkd.2001.29221
[13]
Patel, R. and Ansari, A. (1979) Serum Angiotensin Converting Enzyme Activity in Patients with Chronic Renal Failure on Long Term Hemodialysis. Clinica Chimica Acta, 92, 491-495. https://doi.org/10.1016/0009-8981(79)90232-8
[14]
Malik, U. and Raizada, V. (2015) Some Aspects of the Renin-Angiotensin-System in Hemodialysis Patients. Kidney and Blood Pressure Research, 40, 614-622. https://doi.org/10.1159/000368537
[15]
Lovati, E., Richard, A., Frey, B.M., Frey, F.J. and Ferrari, P. (2001) Genetic Polymorphisms of the Renin-Angiotensin-Aldosterone System in End-Stage Renal Disease. Kidney International, 60, 46-54. https://doi.org/10.1046/j.1523-1755.2001.00769.x
[16]
Kobori, H. and Navar, L.G. (2011) Urinary Angiotensinogen as a Novel Biomarker of Intrarenal Renin-Angiotensin System in Chronic Kidney Disease. International Review of Thrombosis, 6, 108-116.
[17]
Ohashi, N., Isobe, S., Ishigaki, S., Suzuki, T., Ono, M., et al. (2017) Intrarenal Renin-Angiotensin System Activity Is Augmented after Initiation of Dialysis. Hypertension Research, 40, 364-370. https://doi.org/10.1038/hr.2016.143
[18]
Sadjadi, J., Kramer, G.L., Yu, C., Welborn, M.B. and Modrall, J.G. (2005) Angiotensin II Exerts Positive Feedback on the Intrarenal Renin-Angiotensin System by an Angiotensin Converting Enzyme-Dependent Mechanism. Journal of Surgical Research, 129, 272-277. https://doi.org/10.1016/j.jss.2005.04.044
[19]
Ahmed, A.K., Kamath, N.S., El Kossi, M. and El Nahas, A.M. (2010) The Impact of Stopping Inhibitors of the Renin-Angiotensin System in Patients with Advanced Chronic Kidney Disease. Nephrology Dialysis and Transplantation, 25, 3977-3982. https://doi.org/10.1093/ndt/gfp511
[20]
Qiao, Y., Shin, J.I., Chen, T.K., Inker, L.A., Coresh, J., Alexander, G.C., et al. (2020) Association between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality among Persons with Low Estimated Glomerular Filtration Rate. Journal of American Medical Association (Internal Medicine), 180, 718-726. https://doi.org/10.1001/jamainternmed.2020.0193
[21]
Walther, C.P., Winkelmayer, W.C., Richardson, P.A., Virani, S.S. and Navaneethan, S.D. (2021) Renin-Angiotensin System Blocker Discontinuation and Adverse Outcomes in Chronic Kidney Disease. Nephrology Dialysis and Transplantation, 36, 1893-1899. https://doi.org/10.1093/ndt/gfaa300
